Literature DB >> 26329789

In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism.

Porntipa Korprasertthaworn1, Thomas M Polasek1, Michael J Sorich1, Andrew J McLachlan1, John O Miners1, Geoffrey T Tucker1, Andrew Rowland2.   

Abstract

Olanzapine (OLZ) is an atypical antipsychotic used in the treatment of schizophrenia and related psychoses. The metabolism of OLZ is complex and incompletely characterized. This study aimed to elucidate the enzymes and pathways involved in the metabolism of OLZ and to determine the kinetics of OLZ oxidation and glucuronidation by human liver microsomes, recombinant cytochrome P450 (rP450) enzymes, and recombinant UDP-glucuronosyltransferase (rUGT) enzymes. An ultra-performance liquid chromatography-mass spectrometry method was developed and validated to quantify OLZ, its four oxidative metabolites (N-desmethyl-OLZ, 2-hydroxymethyl-OLZ, 7-hydroxy-OLZ, and OLZ-N-oxide), and two N-glucuronides (OLZ-10-N-glucuronide and OLZ-4'-N-glucuronide). Consistent with previous reports, UGT1A4, CYP1A2, and flavin-containing monooxygenase 3 play major roles in catalyzing the formation of OLZ-10-N-glucuronide, 7-hydroxy-OLZ, and OLZ-N-oxide, respectively. In addition, a previously uncharacterized major contribution of CYP2C8 to OLZ-N-demethylation was demonstrated. The kinetics of OLZ metabolite formation (Km and Vmax) by human liver microsomes, rP450 enzymes, and rUGT enzymes were characterized in the presence of bovine serum albumin [2% (w/v)]. Consistent with the known effect of bovine serum albumin on CYP1A2, CYP2C8, and UGT1A4 activities, Km values reported here are lower than previously reported values for OLZ metabolic pathways. In addition to CYP1A2-mediated OLZ-N-demethylation, these results suggest that other P450 enzymes, particularly CYP2C8, contribute significantly to oxidative OLZ metabolism through catalysis of OLZ-N-demethylation.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26329789     DOI: 10.1124/dmd.115.064790

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.

Authors:  Lei Sun; David McDonnell; Miao Yu; Vipul Kumar; Lisa von Moltke
Journal:  Clin Drug Investig       Date:  2019-05       Impact factor: 2.859

2.  The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.

Authors:  J A Arnaiz; C Rodrigues-Silva; G Mezquida; S Amoretti; M J Cuesta; D Fraguas; A Lobo; A González-Pinto; M C Díaz-Caneja; I Corripio; E Vieta; I Baeza; A Mané; C García-Rizo; M Bioque; J Saiz; M Bernardo; S Mas
Journal:  Psychopharmacology (Berl)       Date:  2020-11-23       Impact factor: 4.530

3.  Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.

Authors:  Andrew Rowland; Warit Ruanglertboon; Madelé van Dyk; Dhilushi Wijayakumara; Linda S Wood; Robyn Meech; Peter I Mackenzie; A David Rodrigues; Jean-Claude Marshall; Michael J Sorich
Journal:  Br J Clin Pharmacol       Date:  2018-11-16       Impact factor: 4.335

4.  Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.

Authors:  Thomas M Polasek; Geoffrey T Tucker; Michael J Sorich; Michael D Wiese; Titus Mohan; Amin Rostami-Hodjegan; Porntipa Korprasertthaworn; Vidya Perera; Andrew Rowland
Journal:  Br J Clin Pharmacol       Date:  2018-01-11       Impact factor: 4.335

5.  Population pharmacokinetics of olanzapine in children.

Authors:  Anil R Maharaj; Huali Wu; Kanecia O Zimmerman; Julie Autmizguine; Rohit Kalra; Amira Al-Uzri; Catherine M T Sherwin; Stuart L Goldstein; Kevin Watt; Jinson Erinjeri; Elizabeth H Payne; Michael Cohen-Wolkowiez; Christoph P Hornik
Journal:  Br J Clin Pharmacol       Date:  2020-07-05       Impact factor: 3.716

6.  Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.

Authors:  Lei Sun; Lisa von Moltke; Karen Rowland Yeo
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-01-31

Review 7.  The Benefits of Olanzapine in Palliating Symptoms.

Authors:  Mellar P Davis; Gareth J Sanger
Journal:  Curr Treat Options Oncol       Date:  2020-11-26

8.  Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.

Authors:  Lei Sun; Sergey Yagoda; Baiyun Yao; Christine Graham; Lisa von Moltke
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

Review 9.  Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone.

Authors:  Paula Soria-Chacartegui; Gonzalo Villapalos-García; Pablo Zubiaur; Francisco Abad-Santos; Dora Koller
Journal:  Front Pharmacol       Date:  2021-07-14       Impact factor: 5.810

10.  Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.

Authors:  Lei Sun; Richard Mills; Brian M Sadler; Bhaskar Rege
Journal:  J Clin Pharmacol       Date:  2021-08-04       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.